Related content

Changes in brain ¹¹C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET

By Kadir Ahmadul   Darreh-Shori Taher   Almkvist Ove   Wall Anders   Långström Bengt   Nordberg Agneta  

Psychopharmacology, Vol. 191, Iss. 4, 2007-05 ,pp. : 1005-1014

Springer Publishing Company

Access to resources Recommend Favorite

The Effects of Aerobic Exercise on Cognitive Function of Alzheimer’s Disease Patients

By  

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 14, Iss. 10, 2015-12 ,pp. : 1292-1297

Bentham Science Publishers

Access to resources Recommend Favorite

Galantamine-induced improvements in cognitive function are not related to alterations in α₄β₂ nicotinic receptors in early Alzheimer’s disease as measured in vivo by 2-[¹⁸F]Fluoro-A-85380 PET

By Ellis J.   Nathan P.   Villemagne V.   Mulligan R.   Saunder T.   Young K.   Smith C.   Welch J.   Woodward M.   Wesnes K.   Savage G.   Rowe C.  

Psychopharmacology, Vol. 202, Iss. 1-3, 2009-01 ,pp. : 79-91

Springer Publishing Company

Access to resources Recommend Favorite

PET and SPECT Radiotracers for Alzheimer’s Disease

By  

Current Medicinal Chemistry, Vol. 22, Iss. 28, 2015-01 ,pp. : 3278-3304

Bentham Science Publishers

Access to resources Recommend Favorite

Association of ATP-binding cassette transporter variants with the risk of Alzheimer’s disease

By Cascorbi Ingolf   Flüh Charlotte   Remmler Cornelia   Haenisch Sierk   Faltraco Frank   Grumbt Maria   Peters Michele   Brenn Anja   Thal Dietmar Rudolf   Warzok Rolf Wolfgang   Vogelgesang Silke  

Pharmacogenomics, Vol. 14, Iss. 5, 2013-04 ,pp. : 485-494

Future Medicine

Access to resources Recommend Favorite